MyMD Pharmaceuticals Enrolls First Person in Stage 2 Clinical Trial of MYMD-1 as a Treatment for Delaying Aging and Increasing Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Firm”), a scientific stage pharmaceutical business committed to extending healthy life expectancy, today announced that the initial individual has been enrolled in the Company’s Stage 2 scientific test of lead candidate MYMD-1, a dental immune regulatory authority medicine, as a therapy for postponing aging as well as broadening healthy life expectancy.

The key endpoint for the Stage 2 double-blind, placebo-controlled professional trial is to achieve a reduction in the distributing levels of (TNF-α), lump necrosis element receptor I (TNFRI) and also IL-6. TNF-α and also IL-6 are the healthy proteins in the body that trigger swelling as well as assist turn on the process of aging. The second actions of the trial will be the safety, tolerability, and pharmacokinetics in this populace of clients.

” In a Phase 1 professional trial of MYMD-1, we showed the medication’s statistically substantial efficacy in reducing levels of TNF-α, a principal in creating pathological aging, in the blood. The FDA has actually accepted TNF-α decrease as the primary endpoint for our Phase 2 research study, which our team believe placements us well for a successful Phase 2 result,” claimed Chris Chapman, M.D., Head Of State, Supervisor as well as Principal Medical Policeman of MyMD. “The initiation of client registration in this research study breakthroughs our goal to reduce the aging process, protect against loss of muscle mass cells in aging, restriction frailty, as well as expand healthy lifespan.”

MyMD has stated that there are no FDA-approved medicines for dealing with aging disorders and expanding healthy and balanced life-span humans, a market expected to be a minimum of $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are one of the most recommended medications by revenue, a worldwide market of around $40 billion annually,2 and also, according to Nature Aging journal,3 a stagnation in maturing that would enhance life span by one year is worth $38 trillion and also by ten years is worth $367 trillion.

In addition to aging, MYMD-1’s distinctive action in regulating the body immune system as well as dealing with persistent inflammation is being created for the treatment of autoimmune illness, including rheumatoid arthritis (RA), several sclerosis (MS), diabetic issues, as well as inflammatory bowel illness.

” We intend to begin writing protocols for a Stage 2 pilot study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The increasing occurrence of rheumatoid joint inflammation as well as other autoimmune and also inflammatory conditions are driving demand for TNF preventions like MYMD-1, as well as our team believe our orally carried out medicine with really reduced poisoning would certainly be disruptive to the $60 billion market for RA if authorized by the FDA for this indication.”

Rheumatoid arthritis influences approximately 40 million individuals globally.4.

About MYMD-1.

Initially established for autoimmune illness, MYMD-1’s key purpose is to slow the aging procedure, avoid sarcopenia and also frailty, as well as expand healthy and balanced life-span. Due to the fact that it can go across the blood-brain obstacle and also access to the main nervous system (CNS), MYMD-1 is likewise placed to be a feasible therapy for brain-related disorders. Its mechanism of activity and efficacy in illness including several sclerosis (MS) and also thyroiditis have been studied with partnerships with a number of scholastic establishments. MYMD-1 is likewise showing promise in pre-clinical research studies as a prospective therapy for message- COVID-19 problems and as an anti-fibrotic as well as anti-proliferation therapeutic.

MYMD-1 has revealed effectiveness in pre-clinical researches in managing the immune system by executing as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a motorist of persistent swelling. Unlike various other therapies, MYMD-1 has actually been shown in these pre-clinical researches to precisely block TNF-α when it becomes overactivated in autoimmune illness and also cytokine storms, but not obstruct it from doing its typical job of being an initial -responder to any routine type of moderate infection. MYMD-1’s simplicity of dental dosing is one more differentiator compared to currently readily available TNF-α blockers, every one of which call for shipment by shot or mixture. No approved TNF prevention has ever been dosed by mouth. Additionally, the drug is not immunosuppressive and also has actually not been shown to trigger the major side effects typical with standard therapies that treat inflammation.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical firm committed to expanding healthy and balanced life expectancy, is concentrated on establishing 2 unique restorative systems that deal with the root causes of disease instead of just addressing the signs. MYMD-1 is a medicine platform based on a clinical phase small particle that controls the immune system to manage TNF-α, which drives chronic inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, increase longevity, and treat autoimmune illness as well as COVID-19- connected clinical depression. The Business’s second medication platform, Supera-CBD, is being established to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) as well as is being developed to address and also surpass the quickly expanding CBD market, which includes both FDA approved medications as well as CBD products not currently regulated as drugs. To learn more, see www.mymd.com.